USA-based generics giant Mylan has received tentative approval from the Food and Drug Administration for its Abbreviated New Drug Application for venlafaxine extended-release capsules 37.5mg, 75mg and 150mg for the treatment of major depressive disorder and generalized anxiety disorder.
The tablets are a generic version of Wyeth Pharmaceutical's Effexor XR Capsules, which had annual US sales of around $3.0 billion in the 12 months ending September 30, 2008, for the three dosage forms, according to IMS Health.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze